Pfizer Inc. Recalls Robitussin Product Due to Label Errors
Published: Jul 12, 2012
Pharmaceutical company Pfizer is voluntarily recalling its cough syrup medicine due to errors in its labeling, the Food and Drug Administration (FDA) said in its advisory. The FDA said Pfizer Consumer Healthcare informed its office of the recall of its Robitussin DM product, which contains Dextromethorphan HBr 15 mg and Guaifenessin 100 mg per 5 mL due to labeling error. "The continuous distribution of the said product present health risk to the consuming sector of the public," the advisory said, which was signed by Nicolas Lutero III, assistant secretary of health and FDA’s officer-in-charge.